TORONTO, April 30, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device […]
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2SKto […]
CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) — CEMATRIX Corporation (TSX: CEMX) (OTCQB:CTXXF) (“CEMATRIX” or the “Company“), a specialty construction […]